miR‑222 is upregulated in epithelial ovarian cancer and promotes cell proliferation by downregulating P27kip1

Sun,Chaoyang; Li,Na; Zhou,Bo; Yang,Zongyuan; Ding,Dong; Weng,Danhui; Meng,Li; Wang,Shixuan; Zhou,Jianfeng; Ma,Ding; Chen,Gang

doi:10.3892/ol.2013.1393

August 2013 Volume 6 Issue 2

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

August 2013 Volume 6 Issue 2

Full Size Image

Article

miR‑222 is upregulated in epithelial ovarian cancer and promotes cell proliferation by downregulating P27kip1

Authors:
- Chaoyang Sun
- Na Li
- Bo Zhou
- Zongyuan Yang
- Dong Ding
- Danhui Weng
- Li Meng
- Shixuan Wang
- Jianfeng Zhou
- Ding Ma
- Gang Chen
View Affiliations / Copyright

Affiliations: Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China
Pages: 507-512
|
Published online on: June 13, 2013

https://doi.org/10.3892/ol.2013.1393
Expand metrics +

Abstract

Epithelial ovarian cancer (EOC) is the leading cause of female reproductive system cancer mortality in females. The majority of cases of ovarian carcinomas are not identified until a late stage. Identifying the molecular changes that occur during the development and progression of ovarian cancer is an urgent requirement. MicroRNAs (miRNAs) have been identified as gene expression regulators that induce mRNA degradation or translation blockade through pairing to the 3' untranslated region (3‑'UTR) of the target mRNAs. In the present study, miR‑222 was observed to be frequently upregulated in ovarian cancer. miR‑222 upregulation induced an enhancement of ovarian cancer cell proliferation potential, possibly by downregulating its target, P27Kip1. A bioinformatic analysis showed that the 3'‑UTR of the P27Kip1 mRNA contained a highly‑conserved putative miR‑222 binding site. Luciferase reporter assays demonstrated that P27Kip1 was a direct target of miR‑222. Consistently, there was an inverse correlation between the P27Kip1 and miR‑222 expression levels in the ovarian cancer cell lines and tissues. Overall, the present results suggest that miR‑222 upregulation in human ovarian cancer may promote ovarian cancer cell proliferation during ovarian carcinogenesis.

View Figures

View References

1.	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
2.	No authors listed. Ovarian cancer, five-year stage-specific relative survival rates (2004–2008). J Natl Cancer Inst. 103:12872011.PubMed/NCBI
3.	Ambros V: The functions of animal microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
4.	Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
5.	Galardi S, Mercatelli N, Giorda E, et al: miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. J Biol Chem. 282:23716–23724. 2007. View Article : Google Scholar : PubMed/NCBI
6.	Miller TE, Ghoshal K, Ramaswamy B, et al: MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem. 283:29897–29903. 2008. View Article : Google Scholar : PubMed/NCBI
7.	Zhang CZ, Zhang JX, Zhang AL, et al: MiR-221 and miR-222 target PUMA to induce cell survival in glioblastoma. Mol Cancer. 9:2292010. View Article : Google Scholar : PubMed/NCBI
8.	Lu Y, Roy S, Nuovo G, et al: Anti-microRNA-222 (anti-miR-222) and -181B suppress growth of tamoxifen-resistant xenografts in mouse by targeting TIMP3 protein and modulating mitogenic signal. J Biol Chem. 286:42292–42302. 2011. View Article : Google Scholar : PubMed/NCBI
9.	Stinson S, Lackner MR, Adai AT, et al: miR-221/222 targeting of trichorhinophalangeal 1 (TRPS1) promotes epithelial-to-mesenchymal transition in breast cancer. Sci Signal. 4:pt52011.PubMed/NCBI
10.	Stinson S, Lackner MR, Adai AT, et al: TRPS1 targeting by miR-221/222 promotes the epithelial-to-mesenchymal transition in breast cancer. Sci Signal. 4:ra412011.PubMed/NCBI
11.	Yang CJ, Shen WG, Liu CJ, et al: miR-221 and miR-222 expression increased the growth and tumorigenesis of oral carcinoma cells. J Oral Pathol Med. 40:560–566. 2011. View Article : Google Scholar : PubMed/NCBI
12.	Wurz K, Garcia RL, Goff BA, et al: MiR-221 and MiR-222 alterations in sporadic ovarian carcinoma: Relationship to CDKN1B, CDKNIC and overall survival. Genes Chromosomes Cancer. 49:577–584. 2010.PubMed/NCBI
13.	Koff A: How to decrease p27Kip1 levels during tumor development. Cancer Cell. 9:75–76. 2006. View Article : Google Scholar : PubMed/NCBI
14.	Duncan TJ, Al-Attar A, Rolland P, Harper S, Spendlove I and Durrant LG: Cytoplasmic p27 expression is an independent prognostic factor in ovarian cancer. Int J Gynecol Pathol. 29:8–18. 2010. View Article : Google Scholar : PubMed/NCBI
15.	Xing H, Wang S, Hu K, et al: Effect of the cyclin-dependent kinases inhibitor p27 on resistance of ovarian cancer multicellular spheroids to anticancer chemotherapy. J Cancer Res Clin Oncol. 131:511–519. 2005. View Article : Google Scholar : PubMed/NCBI
16.	Masciullo V, Sgambato A, Pacilio C, et al: Frequent loss of expression of the cyclin-dependent kinase inhibitor p27 in epithelial ovarian cancer. Cancer Res. 59:3790–3794. 1999.PubMed/NCBI
17.	Greither T, Grochola LF, Udelnow A, Lautenschlager C, Würl P and Taubert H: Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. Int J Cancer. 126:73–80. 2010. View Article : Google Scholar : PubMed/NCBI
18.	Visone R, Russo L, Pallante P, et al: MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr Relat Cancer. 14:791–798. 2007. View Article : Google Scholar : PubMed/NCBI
19.	Quintavalle C, Garofalo M, Zanca C, et al: miR-221/222 over-expression in human glioblastoma increases invasiveness by targeting the protein phosphate PTPμ. Oncogene. 31:858–868. 2012. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

miR‑222 is upregulated in epithelial ovarian cancer and promotes cell proliferation by downregulating P27kip1

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Related Articles